The “Net Innovation Trend” and What It Means for Big Pharmas, Biotechs, and Generics
By Mark P. Mathieu
Innovation is the key value driver in healthcare. Over the past 8 years, the pharmaceuticals sector has lost a stunning $593 billion (-65%) in market cap while the two sectors with innovation – biotech and med tech – have each added $71 billion (+46%) and $19 billion (+6%) in market cap, respectively. Read More
|
|
Complete Genomics Files $86-Million IPO
TODAY
|
San Jose Mercury News | Next-generation sequencing service provider Complete Genomics has filed papers for an initial public offering (IPO) that could be worth $86 million. The company's proposed stock ticker symbol is GNOM.
more
2010 Best Practices Awards Winners
Jul 30
|
Bio-IT World | Last April, we handed out the Bio•IT World 2010 Best Practices Awards at a lavish awards ceremony in Boston during the Bio-IT World Conference & Expo. Here you’ll find profiles of the six category winners and three other awards: the Editors’ Choice Award, the Judges’ Prize, and a Community Service Award.
more
Dell Buys Ocarina
Jul 28
|
ZDNet | Dell is buying deduplication startup Ocarina, winner of the 2010 Bio-IT World Best of Show award in IT Hardware and Infrastructure.
more
Generic Drug Approvals Picking Up?
Jul 27
|
Forbes | The FDA approved Novartis' generic blood thinner after a four-year review, maybe signaling more generic approvals in the coming year.
more
Sanofi-Aventis Bids for Genzyme--Updated
Jul 27
|
Bloomberg | Over the weekend, rumors swirled that Sanofi-Aventis had made a bid for Genzyme about two weeks ago. Today, however Bloomberg has reported that Genzyme has rebuffed the approach last week.
more
 | The Role of Analytics in Transforming Healthcare Sharing many of the data challenges and opportunities faced by Healthcare, the Life Sciences industry remains focused on delivering new, innovative therapies and solutions to patients in a cost effective, timely and safe way. With spiraling R&D costs, new methods such as adaptive trials, and never ending need for deep pharmacovigilance, the Life Sciences companies that effectively use analytics to explore, monitor and optimize their business will rapidly become the new leaders. Oracle’s strategy—built upon Enterprise Health Analytics and Health Data Warehouse Foundation—provides a powerful, practical, and extensible approach to delivering the IT analytics infrastructure required to confront the worldwide healthcare challenge. |  | BPM-Based Case Management Approach to Optimizing Clinical Trial Efficiency Business Process Management (BPM) software offers liberation in the planning and management of clinical trials today. SmartBPM provides the components for automating critical clinical trial processes ranging from protocol development and patient enrollment to site management and investigator payments. Advantages are: - Potentially stunning return on investment at multiple levels.
- A 500%, or better, increase in application development time by directly executing business requirements
- Improved customer retention
- A 50% possible reduction in training time
Discovered is opportunity to enhance relationships with investigators, subjects, and regulators while bringing momentum to a technology-impaired study startup phase. Learn more about SmartBPM in this complimentary white paper. |  | Next-gen Cloud-based eClinical New technologies are available to leverage Cloud Computing in managing clinical trial data. This paper discusses a next generation eClinical
platform that: - Speeds trial set up
- Accommodates changes with zero downtime
- Integrates effectively with other clinical trial technology systems
It is offered with either software-as-a-service (SaaS), or turnkey infrastructure options in which the user organization operates their own cloud using their IT teams, within their data centers. Read this paper to learn and decide how best to leverage cloud computing’s many strengths for your organization’s particular needs. |
Medidata Solutions
Evaluating a Risk-based Approach to Good Clinical Practice
.gif?n=6512 "medidata5_podcast") The verification of source documents by study monitors at investigational sites is considered a good clinical practice by regulatory authorities overseeing clinical research, and is extremely important to ensuring data quality in clinical trials. Today’s challenging environment is prompting study teams to explore the use of risk-based approaches to monitoring that do not compromise data quality, but allow limited resources to be directed more effectively to where they’re most needed and to the most critical review activities.
In this podcast, industry experts and executives from Medidata will address questions such as:
- Why are regulatory agencies and industry open to evaluating the new approaches in site monitoring and source document verification (SDV), and what attitudes and reactions towards less than 100% SDV?
- What factors do research sponsors need to consider in adopting risk-based site monitoring?
Download Now
|
|
Jul 22, 2010
| Bio-IT World |
FULL STORIES
- Collexis launches community module for its Expert Profiling application
- St. Jude Children's Research Hospital develops genomics-based approach to cancer subgroups
- Silence Therapeutics extends AstraZeneca deal
- Pfizer and Samsung Medical Center start liver cancer collaboration
Bio-IT Weekly Update
eCliniqua
Pharma Services News
Software Engineer – Computational Biology Center
Memorial Sloan-Kettering Cancer Center seeks an Engineer to design and develop complex data analysis systems in support of cancer genomics research projects at the Computational Biology Center. Qualified candidate will have a BA, 5+ years of software development experience and expert knowledge of Java, SQL, and HTML.
Apply: www.mskcciscareers.org. Equal opportunity and affirmative action employer.
|